Anti-insulin receptor autoantibodies are not required for type 2 diabetes pathogenesis in NZL/Lt mice, a New Zealand obese (NZO)-derived mouse strain

Experimental Diabesity Research

Volumn 5, Issue 3, 2004, Pages 177-185

  McInerney, Marcia F ^a   Najjar, Sonia M ^b   Brickley, Deanna ^a   Lutzke, Mary ^a   Abou Rjaily, George A ^b   Reifsnyder, Peter ^c   Haskell, Bradford D ^c   Flurkey, Kevin ^c   Zhang, Ying Jian ^d   Pietropaolo, Susan L ^d   Pietropaolo, Massimo ^d   Byers, James P ^a   Leiter, Edward H ^c  

^a UNIVERSITY OF TOLEDO   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c JACKSON LABORATORY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; B lymphocytes; Insulin receptor; New Zealand obese (NZO) mice; Type 2 diabetes mellitus

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M ANTIBODY; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR ANTIBODY;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACKCROSSING; BREEDING; CELL LOSS; CHO CELL; CHRONIC DISEASE; COMPARATIVE STUDY; CONGENIC STRAIN; CONTROLLED STUDY; FLOW CYTOMETRY; FREQUENCY ANALYSIS; GENE DISRUPTION; GENE SEGREGATION; GENETIC TRANSFECTION; HYPERGLYCEMIA; INBREEDING; INSULIN RESISTANCE; INSULITIS; MALE; MEDICAL RESEARCH; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT GAIN; WILD TYPE;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS, TYPE 2; GENES, IMMUNOGLOBULIN; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; OBESITY; RECEPTOR, INSULIN; TIME FACTORS; TRANSFECTION;

EID: 6344235750     PISSN: 15438600     EISSN: None     Source Type: Journal    
DOI: 10.1080/15438600490478029     Document Type: Article

References (20)

1. Bielchowsky, M., and Bielschowsky, F. (1956) The New Zealand strain of obese mice. Their response to stilbestrol and to insulin. Aust. J. Exp. Biol., 34, 77-97.
2. Veroni, M. C., Proietto, J., and Larkins, R. G. (1991) Evolution of insulin resistance in New Zealand obese mice. Diabetes 40, 1480-1487.
3. Leiter, E. H., Reifsnyder, P. C., Flurkey, K., Partke, H-J., Junger, E., and Herberg, L. (1998) Non-insulin dependent diabetes genes in mice: Deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes, 47, 1287-1295.
4. Melez, K. A., Attallah, A. M., Harrison, E. T., and Raveche, E. S. (1985) Immune abnormalities in the diabetic New Zealand obese (NZO) mouse: Insulin treatment partially suppresses splenic hyperactivity measured by flow cytometry analysis. Clin. Immunol. Immunopathol., 36, 110-119.
5. Melez, K. A., Harrison, L. C., Gilliam, J. N., and Steinberg, A. D. (1980) Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse. Diabetes, 29, 835-840.
6. Harrison, L. C., and Itin, A. (1979) A possible mechanism for insulin resistance and hyperglycemia in NZO mice. Nature, 279, 334-336.
7. Haskell, B. D., Flurkey, K., Duffy, T. M., Sargent, E. E., and Leiter, E. H. (2002) The diabetes-prone NZO/H1 strain. I. Immunophenotypic comparison to the related NZB/BinJ and NZW/LacJ strains. Lab. Invest., 82, 833-842.
8. Junger, E., Herberg, L., Jeruschke, K., and Leiter, E. H. (2002) The diabetes-prone NZO/H1 strain: II. Pancreatic immunopathology. Lab. Invest., 82, 843-853.
9. Kitamura, D., Roes, J., Kuhn, R., and Rajewsky, K. (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature, 350, 423-426.
10. Taguchi, N., Hashimoto, Y., Hsu, T., Ansari, A. A., Shultz, L., Dorshkind, K., Ikehara, S., Naiki, M., and Gershwin, M. E. (2001 B cells are selectively associated with thymic cortical but not medullary pathology in NZB mice. J. Autoimmun., 16, 393-400.
11. Swick, A. G., Janicot, M., Cheneval-Kastelic, T., McLenithan, J. C., and Lane, M. D. (1992) Promoter-cDNA-directed heterologous protein expression in Xenopus laevis oocytes. Proc. Natl. Acad. Sci. U. S. A., 84, 1812-1816.
12. Zapf, A., Hsu, D., and Olefsky, J. M. (1994) Comparison of the intracellular itineraries of insulin-like growth factor-I and insulin and their receptors in Rat-1 fibroblasts. Endocrinology, 134, 3445-3452.
13. Formisano, P., Najjar, S. M., Gross, C. N., Philippe, N., Oriente, F., Kern-Buell, C. L., Accili, D., and Gorden, P. (1995) Receptor mediated internalization of insulin. Potential role of pp120/HA4, a substrate of the insulin receptor kinase. J. Biol. Chem. 270, 24073-24077.
14. Whittaker, J., Okamoto, A. K., Thys, R., Bell, G. I., Steiner, D. F., and Hofmann, C. A. (1987) High level expression of human insulin receptor cDNA in mouse NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A., 84, 5237-5241.
15. Reifsnyder, P. C., and Leiter, E. H. (2002) Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes., 51, 825-832.
16. Leiter, E. H., Prochazka, M., and Shultz, L. D. (1987) Effect of immunodeficiency on diabetogenesis in genetically diabetic (db/db) mice. J. Immunol., 138, 3224-3229.
17. Leiter, E. H., Reifsnyder, P. C., Flurkey, K., Partke, H. J., Junger, E., and Herberg, L. (1998) NIDDM genes in mice: Deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes, 47, 1287-1295.
18. Van Obberghen, E., Grunfeld, C., Harrison, L. C., Karlsson, A., Muggeo, M., and Kahn, C. R. (1982) Autoantibodies to the insulin receptor and insulin-resistant diabetes. Horm. Res., 16, 280-288.
19. Kahn, C. R., Kasuga, M., King, G. L., and Grunfeld, C. (1982) Autoantibodies to insulin receptors in man: Immunological determinants and mechanisms of action. Ciba Found. Symp., 90, 91-113.
20. Auclair, M., Vigouroux, C., Desbois-Mouthon, C., Deibener, J., Kaminski, P., Lascols, O.,Cherqui, G., Capeau, J., and Caron, M. (1999) Antiinsulin receptor antibodies induce insulin receptors to constitutively associate with insulin receptor substrate 1 and 2 and cause severe cell resistance to both insulin and insulin-like growth factor 1. J. Clin. Endocrinol. Metab., 84, 3197-3206.